Replies to post #185933 on NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

Correction. I meant to opine that mesenchymal plus classical would easily make up more than 50% of the entire glio IV population and would be predominant in the M- population.

[flipper44]

I understand your viewpoint that Proneural is likely dominated by methylated MGMT, whereas Mesenchymal by unmethylated. However, when these trend studies arrive, I find that they are often contested by other studies. For instance, I would not be surprised to find mesenchymal has a high percentage of inconsistent methylated. Also, methylated MGMT typically makes up about 40% in a typical cross section where researchers also include inconsistent methylated as methylated MGMT. Proneural only typically makes up 13% of a typical cross section of GBM patients. Then there is the subtype within proneural known as G-cimp proneural -- and I can't remember off the top of my head which is more likely to contain more methylated MGMT, but I think it is the G-cimp (I could have it backwards), which is the subtype of proneural that apparently might respond to SOC and perhaps DCVax-L. I can see why Dr. Prins and Dr. Liau hypothesized in their early trials that DCVax-L likely helps mesenchymal, but I think they had far too small of a sampling to draw any firm opinions about proneural. If I recall, one of their early proneural patients faired quite well -- even for a proneural patient.

And again, we cannot forget the exclusion criteria placing pure psPD into yet another group of 32.